Showa Denko
In 2019, Hitachi sold its medical imaging business to Fujifilm for US$1.7 billion. Showa Denko bought Hitachi Chemical from Hitachi and other shareholders, at US$42.97 per share. Until then, Hitachi Chemical had been considered to be a core unit of the group. Hitachi also suspended the ABWR development by its British subsidiary Horizon Nuclear Power as it did not provide an adequate "economic rationality as a private enterprise" to proceed.